Zhifei Biological Products
Update in progress300122.SZ (Shenzhen)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Chongqing Zhifei Biological Products Co., Ltd. develops, manufactures, markets, distributes, imports, and exports vaccines in China. Its product line includes Recombinant Novel Coronavirus Vaccine (CHO cells); Recombinant Mycobacterium tuberculosis Fusion Protein (Ekear); Haemophilus influenzae type b vaccine (XiFeiBei); ACYW135 meningococcal polysaccharide vaccine (Menwayc); Mycobacterium vaccae for injection (Vaccae); meningococcal Groups A and C polysaccharide conjugate vaccine (Mening A Con); and other products. The company also offers cold storage services and was founded in 2002, based in Chongqing.
Company score
- Sentiment
- 0.46
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.11
- Governance
- 0.14
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.06
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.26
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!